Gilead Sciences outlines its outlook for fiscal year 2026 in its latest report.
Show original
The company expects that, excluding adverse factors brought by policy changes, sales of its core business segment—HIV treatment drugs—will achieve steady growth, with fiscal year 2026 projected to increase by approximately 8% compared to fiscal year 2025. This growth expectation highlights the company’s continued market advantage and development potential in the antiviral field.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
Hyperliquid has released multiple USDH feature updates, HIP-4 Outcome Markets is now live on the testnet
BlockBeats•2026/03/11 02:21
Bernstein: The impact of Middle East tensions on TSMC is manageable
金十•2026/03/11 02:11
Data: Three addresses have accumulated a total of 49,424 ETH, with a total value exceeding 100 million USD.
Chaincatcher•2026/03/11 02:07
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$69,981.27
+1.16%
Ethereum
ETH
$2,033.93
+0.84%
Tether USDt
USDT
$1
+0.01%
BNB
BNB
$642.37
+0.54%
XRP
XRP
$1.39
+1.09%
USDC
USDC
$1.0000
+0.00%
Solana
SOL
$86.04
+0.40%
TRON
TRX
$0.2860
+0.09%
Dogecoin
DOGE
$0.09320
+2.51%
Cardano
ADA
$0.2602
+0.76%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now